The apparent solution of this problem is to combine, in a carefully coordinated manner discussed above, the transient suppression of the neuronal integrated stress response with the concurrent activation of BACE1 and/or BACE2 (or with the concurrent utilization of any other suitable iAβ-degrading agent) in one composite therapy for AD. The gene discussed is BACE2; the disease is Alzheimer disease.